Health economic evidence for adjuvant chemotherapy in stage II and III colon cancer: a systematic review
Abstract Objective The aims of this study was to appraise the health economic evidence for adjuvant chemotherapy (AC) strategies in stage II and III colon cancer (CC) and identify gaps in the available evidence that might inform further research. Method A systematic review of published economic eval...
Main Authors: | Yat Hang To, Peter Gibbs, Jeanne Tie, Maarten IJzerman, Koen Degeling |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2023-01-01
|
Series: | Cost Effectiveness and Resource Allocation |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12962-023-00422-2 |
Similar Items
-
Cost‐effectiveness of adjuvant chemotherapy for high‐risk stage II and stage III colon cancer in South Africa
by: Sarah Xinhui Tan, et al.
Published: (2023-07-01) -
Adjuvant Chemotherapy Benefit in Elderly Stage II/III Colon Cancer Patients
by: Xin Chen, et al.
Published: (2022-06-01) -
Real-life experiences and barriers to adjuvant chemotherapy in Saudi patients with advanced stage II and stage III colon cancer
by: Mesnad S Alyabsi, et al.
Published: (2024-01-01) -
The effect of smoking, obesity and diabetes on recurrence‐free and overall survival in patients with stage III colon cancer receiving adjuvant chemotherapy
by: Alex Croese, et al.
Published: (2021-06-01) -
Duration of FOLFOX Adjuvant Chemotherapy in High-Risk Stage II and Stage III Colon Cancer With Deficient Mismatch Repair
by: Huabin Hu, et al.
Published: (2020-12-01)